Julian Grosskreutz

List of Publications by Year in descending order

145 papers	6,972 citations	61984 43 h-index	74163 75 g-index
160 all docs	160 docs citations	160 times ranked	8248 citing authors

#	Article	IF	Citations
1	Medical therapies for amyotrophic lateral sclerosis-related respiratory decline: an appraisal of needs, opportunities and obstacles. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 66-75.	1.7	1
2	Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis. JAMA Neurology, 2022, 79, 121.	9.0	78
3	Classification of amyotrophic lateral sclerosis by brain volume, connectivity, and network dynamics. Human Brain Mapping, 2022, 43, 681-699.	3.6	17
4	Cerebrospinal fluid biomarkers of disease activity and progression in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 422-435.	1.9	22
5	Use and subjective experience of the impact of motor-assisted movement exercisers in people with amyotrophic lateral sclerosis: a multicenter observational study. Scientific Reports, 2022, 12, .	3.3	2
6	Disease aggressiveness signatures of amyotrophic lateral sclerosis in white matter tracts revealed by the ‹scp›D50‹/scp› disease progression model. Human Brain Mapping, 2021, 42, 737-752.	3.6	16
7	ALS and fertility: does ALS affect number of children patients have?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 94-100.	1.7	0
8	Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis. NeuroImage: Clinical, 2021, 30, 102674.	2.7	12
9	Chitotriosidase as biomarker for early stage amyotrophic lateral sclerosis: a multicenter study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 276-286.	1.7	14
10	Cardiovascular comorbidities in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2021, 421, 117292.	0.6	10
11	Impact of subthreshold depression on health-related quality of life in patients with Parkinsonâ€™s disease based on cognitive status. Health and Quality of Life Outcomes, 2021, 19, 107.	2.4	6
12	Cerebrospinal Fluid Neurofilament Light Chain (NfL) Predicts Disease Aggressiveness in Amyotrophic Lateral Sclerosis: An Application of the D50 Disease Progression Model. Frontiers in Neuroscience, 2021, 15, 651651.	2.8	24
13	Monocyte-Derived Macrophages Contribute to Chitinase Dysregulation in Amyotrophic Lateral Sclerosis: A Pilot Study. Frontiers in Neurology, 2021, 12, 629332.	2.4	6
14	Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen. European Journal of Neurology, 2021, 28, 2582-2595.	3.3	16
15	Motor neuron disease beginning with frontotemporal dementia: clinical features and progression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 508-516.	1.7	7
16	Delayed Diagnosis and Diagnostic Pathway of ALS Patients in Portugal: Where Can We Improve?. Frontiers in Neurology, 2021, 12, 761355.	2.4	12
17	Circulating miR-181 is a prognostic biomarker for amyotrophic lateral sclerosis. Nature Neuroscience, 2021, 24, 1534-1541.	14.8	57
18	Bloodâ€“Brain Barrier Disruption Is Not Associated With Disease Aggressiveness in Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2021, 15, 656456.	2.8	11

#	Article	IF	Citations
19	Peripheral neuropathy in ALS: phenotype association. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1133-1134.	1.9	3
20	Common and rare variant association analyses in amyotrophic lateral sclerosis identify 15 risk loci with distinct genetic architectures and neuron-specific biology. Nature Genetics, 2021, 53, 1636-1648.	21.4	223
21	Cognitive deficits have only limited influence on health-related quality of life in amyotrophic lateral sclerosis. Aging and Mental Health, 2020, 24, 1963-1967.	2.8	4
22	Effect of Highâ€Caloric Nutrition on Survival in Amyotrophic Lateral Sclerosis. Annals of Neurology, 2020, 87, 206-216.	5.3	105
23	Applying the D50 disease progression model to gray and white matter pathology in amyotrophic lateral sclerosis. NeuroImage: Clinical, 2020, 25, 102094.	2.7	19
24	Effect of high-caloric nutrition on serum neurofilament light chain levels in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1007-1009.	1.9	36
25	Triage of Amyotrophic Lateral Sclerosis Patients during the COVID-19 Pandemic: An Application of the D50 Model. Journal of Clinical Medicine, 2020, 9, 2873.	2.4	6
26	Use of vitamins by participants in amyotrophic lateral sclerosis clinical trials. PLoS ONE, 2020, 15, e0237175.	2.5	4
27	Emotional Lability at Disease Onset Is an Independent Prognostic Factor of Faster Disease Progression in Amyotrophic Lateral Sclerosis. , 2020, 11, 1021.		5
28	Modelling disease course in amyotrophic lateral Sclerosis: pseudo-longitudinal insights from cross-sectional health-related quality of life data. Health and Quality of Life Outcomes, 2020, 18, 117.	2.4	14
29	Association between malnutrition, clinical parameters and health-related quality of life in elderly hospitalized patients with Parkinsonâ€™s disease: A cross-sectional study. PLoS ONE, 2020, 15, e0232764.	2.5	12
30	Spreading in ALS: The relative impact of upper and lower motor neuron involvement. Annals of Clinical and Translational Neurology, 2020, 7, 1181-1192.	3.7	34
31	The Chitinases as Biomarkers for Amyotrophic Lateral Sclerosis: Signals From the CNS and Beyond. Frontiers in Neurology, 2020, 11, 377.	2.4	25
32	Potential Preventive Strategies for Amyotrophic Lateral Sclerosis. Frontiers in Neuroscience, 2020, 14, 428.	2.8	11
33	Family history of neurodegenerative disorders in patients with amyotrophic lateral sclerosis: population-based caseâ€“control study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 671-672.	1.9	3
34	Experiences from treating seven adult 5q spinal muscular atrophy patients with Nusinersen. Therapeutic Advances in Neurological Disorders, 2020, 13, 175628642090780.	3.5	36
35	Sicca Symptoms in Parkinsonâ€™s Disease: Association with Other Nonmotor Symptoms and Health-Related Quality of Life. Parkinson's Disease, 2020, 2020, 1-7.	1.1	7
36	Occasional essay: Upper motor neuron syndrome in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 227-234.	1.9	26

#	Article	IF	Citations
37	Impact of comorbidities and co-medication on disease onset and progression in a large German ALS patient group. Journal of Neurology, 2020, 267, 2130-2141.	3.6	23
38	Symptomatic pharmacotherapy in ALS: data analysis from a platform-based medication management programme. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 783-785.	1.9	15
39	A proposal for new diagnostic criteria for ALS. Clinical Neurophysiology, 2020, 131, 1975-1978.	1.5	268
40	What Predicts Different Kinds of Nonadherent Behavior in Elderly People With Parkinson's Disease?. Frontiers in Medicine, 2020, 7, 103.	2.6	16
41	Data on adherence to medication in neurological patients using the German Stendal Adherence to Medication Score (SAMS). Data in Brief, 2019, 23, 103855.	1.0	9
42	Reply: Adult-onset distal spinal muscular atrophy: a new phenotype associated with KIF5A mutations. Brain, 2019, 142, e67-e67.	7.6	1
43	A next generation setup for pre-fractionation of non-denatured proteins reveals diverse albumin proteoforms each carrying several post-translational modifications. Scientific Reports, 2019, 9, 11733.	3.3	7
44	Poor emotional well-being is associated with rapid progression in amyotrophic lateral sclerosis. ENeurologicalSci, 2019, 16, 100198.	1.3	7
45	162.â€ƒCLUSTER ANALYSIS TO EXPLORE CLINICAL SUBCLASSIFICATION OF EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (CHURGâ€“STRAUSS). Rheumatology, 2019, 58, .	1.9	0
46	Comparison of anonymous versus nonanonymous responses to a medication adherence questionnaire in patients with Parkinson’s disease . Patient Preference and Adherence, 2019, Volume 13, 151-155.	1.8	14
47	Plasma VCAM1 levels correlate with disease severity in Parkinsonâ€™s disease. Journal of Neuroinflammation, 2019, 16, 94.	7.2	37
48	Influence of Environment and Lifestyle on Incidence and Progress of Amyotrophic Lateral Sclerosis in A German ALS Population. , 2019, 10, 205.		18
49	Biomarkers for Dementia, Fatigue, and Depression in Parkinson's Disease. Frontiers in Neurology, 2019, 10, 195.	2.4	15
50	Prognostic factors in ALS: a comparison between Germany and China. Journal of Neurology, 2019, 266, 1516-1525.	3.6	46
51	Clusters of non-adherence to medication in neurological patients. Research in Social and Administrative Pharmacy, 2019, 15, 1419-1424.	3.0	27
52	Assessment of the reliability of the motor unit size index (MUSIX) in single subject â€œround-robinâ€•and multi-centre settings. Clinical Neurophysiology, 2019, 130, 666-674.	1.5	13
53	Reaction to Endoplasmic Reticulum Stress via ATF6 in Amyotrophic Lateral Sclerosis Deteriorates With Aging. Frontiers in Aging Neuroscience, 2019, 11, 5.	3.4	49
54	Investigation of mitochondrial calcium uniporter role in embryonic and adult motor neurons from G93AhSOD1 mice. Neurobiology of Aging, 2019, 75, 209-222.	3.1	11

#	Article	IF	Citations
55	Disease progression impacts health-related quality of life in amyotrophic lateral sclerosis. Journal of the Neurological Sciences, 2019, 397, 92-95.	0.6	17
56	Interferonâ€î³ Receptor 1 and GluR1 upregulated in motor neurons of symptomatic hSOD 1G93A mice. European Journal of Neuroscience, 2019, 49, 62-78.	2.6	4
57	Cerebral patterns of neuropsychological disturbances in hepatitis C patients. Journal of NeuroVirology, 2019, 25, 229-238.	2.1	16
58	A family with limb girdle muscular dystrophy type 1B and multiple exostoses. , 2019, 38, 225-232.		1
59	The metabolic and endocrine characteristics in spinal and bulbar muscular atrophy. Journal of Neurology, 2018, 265, 1026-1036.	3.6	29
60	Hot-spot KIF5A mutations cause familial ALS. Brain, 2018, 141, 688-697.	7.6	167
61	Comprehensive analysis of the mutation spectrum in 301 German ALS families. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 817-827.	1.9	80
62	Provision of assistive technology devices among people with ALS in Germany: a platform-case management approach. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2018, 19, 342-350.	1.7	33
63	Dysregulation of chemokine receptor expression and function in leukocytes from ALS patients. Journal of Neuroinflammation, 2018, 15, 99.	7.2	20
64	Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurology, The, 2018, 17, 423-433.	10.2	342
65	Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis. Neurology, 2018, 90, e22-e30.	1.1	148
66	Developing a Neuroimaging Biomarker for Amyotrophic Lateral Sclerosis: Multi-Center Data Sharing and the Road to a â€œGlobal Cohortâ€. Frontiers in Neurology, 2018, 9, 1055.	2.4	10
67	Neurofascin-155 IgM autoantibodies in patients with inflammatory neuropathies. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1145-1151.	1.9	31
68	Safety and efficacy of rasagiline as an add-on therapy to riluzole in patients with amyotrophic lateral sclerosis: a randomised, double-blind, parallel-group, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2018, 17, 681-688.	10.2	51
69	Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurology, The, 2017, 16, 208-216.	10.2	62
70	Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease. Neurology, 2017, 88, 2302-2309.	1.1	169
71	July 2017 ENCALS statement on edaravone. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 471-474.	1.7	41
72	Sigma 1 receptor activation modifies intracellular calcium exchange in the G93AhSOD1 ALS model. Neuroscience, 2017, 359, 105-118.	2.3	22

#	Article	IF	Citations
73	International Survey of ALS Experts about Critical Questions for Assessing Patients with ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 505-510.	1.7	17
74	â€˜Itâ€™s the progression, doctorâ€™: what patients with motor neurone disease really are interested in. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 897-897.	1.9	0
75	Diagnostic and prognostic significance of neurofilament light chain NF-L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: Data from the German MND-net. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 112-119.	1.7	63
76	Neuroimaging Endpoints in Amyotrophic Lateral Sclerosis. Neurotherapeutics, 2017, 14, 11-23.	4.4	72
77	DNA strand breaks and TDP-43 mislocation are absent in the murine hSOD1G93A model of amyotrophic lateral sclerosis in vivo and in vitro. PLoS ONE, 2017, 12, e0183684.	2.5	12
78	Assessment of pulmonary function in amyotrophic lateral sclerosis: when can polygraphy help evaluate the need for non-invasive ventilation?. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 1022-1026.	1.9	33
79	Critical illness polyneuropathy in ICU patients is related to reduced motor nerve excitability caused by reduced sodium permeability. Intensive Care Medicine Experimental, 2016, 4, 10.	1.9	21
80	Multicenter validation of CSF neurofilaments as diagnostic biomarkers for ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2016, 17, 404-413.	1.7	84
81	Down-regulation of purinergic P2X7 receptor expression and intracellular calcium dysregulation in peripheral blood mononuclear cells of patients with amyotrophic lateral sclerosis. Neuroscience Letters, 2016, 630, 77-83.	2.1	29
82	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nature Genetics, 2016, 48, 1043-1048.	21.4	494
83	The intricacy of biomarker complexityâ€“the identification of a genuine proteomic biomarker is more complicated than believed. Proteomics - Clinical Applications, 2016, 10, 1073-1076.	1.6	6
84	Assessment of the upper motor neuron in amyotrophic lateral sclerosis. Clinical Neurophysiology, 2016, 127, 2643-2660.	1.5	87
85	Alterations in the hypothalamic melanocortin pathway in amyotrophic lateral sclerosis. Brain, 2016, 139, 1106-1122.	7.6	80
86	A large-scale multicentre cerebral diffusion tensor imaging study in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 570-579.	1.9	138
87	Quality Control of Motor Unit Number Index (MUNIX) Measurements in 6 Muscles in a Single-Subject â€œRound-Robinâ€•Setup. PLoS ONE, 2016, 11, e0153948.	2.5	40
88	Relation of Resting Membrane Polarization and Insulin Resistance in Critically Ill Patients. Intensive Care Medicine Experimental, 2015, 3, .	1.9	1
89	Progress towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurology, The, 2015, 14, 786-788.	10.2	38
90	Mind the gap: The mismatch between clinical and imaging metrics in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2015, 16, 524-529.	1.7	65

#	Article	IF	Citations
91	Novel computer vision algorithm for the reliable analysis of organelle morphology in whole cell 3D images â€" A pilot study for the quantitative evaluation of mitochondrial fragmentation in amyotrophic lateral sclerosis. Mitochondrion, 2015, 25, 49-59.	3.4	8
92	Obsessive-compulsive disorder is a heterogeneous disorder: evidence from diffusion tensor imaging and magnetization transfer imaging. BMC Psychiatry, 2015, 15, 135.	2.6	28
93	Relationships Between Disease Severity, Social Support and Health-Related Quality of Life in Patients with Amyotrophic Lateral Sclerosis. Social Indicators Research, 2015, 120, 871-882.	2.7	20
94	Muscle ultrasonography as an additional diagnostic tool for the diagnosis of amyotrophic lateral sclerosis. Clinical Neurophysiology, 2015, 126, 820-827.	1.5	88
95	Susceptibility-Weighted Imaging Provides Insight into White Matter Damage in Amyotrophic Lateral Sclerosis. PLoS ONE, 2015, 10, e0131114.	2.5	15
96	Transcranial brainstem sonography as a diagnostic tool for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2014, 15, 244-249.	1.7	12
97	Endoplasmic reticulum stress is accompanied by activation of NF-Î²B in amyotrophic lateral sclerosis. Journal of Neuroimmunology, 2014, 270, 29-36.	2.3	43
98	Tics are caused by alterations in prefrontal areas, thalamus and putamen, while changes in the cingulate gyrus reflect secondary compensatory mechanisms. BMC Neuroscience, 2014, 15, 6.	1.9	53
99	The ER mitochondria calcium cycle and ER stress response as therapeutic targets in amyotrophic lateral sclerosis. Frontiers in Cellular Neuroscience, 2014, 8, 147.	3.7	98
100	Voxel-Based MRI Intensitometry Reveals Extent of Cerebral White Matter Pathology in Amyotrophic Lateral Sclerosis. PLoS ONE, 2014, 9, e104894.	2.5	19
101	Extent of cortical involvement in amyotrophic lateral sclerosis â€" an analysis based on cortical thickness. BMC Neurology, 2013, 13, 148.	1.8	41
102	Structural brain abnormalities in cervical dystonia. BMC Neuroscience, 2013, 14, 123.	1.9	53
103	Calcium-dependent protein folding in amyotrophic lateral sclerosis. Cell Calcium, 2013, 54, 132-143.	2.4	51
104	Proteome analysis of body fluids for amyotrophic lateral sclerosis biomarker discovery. Proteomics - Clinical Applications, 2013, 7, 123-135.	1.6	30
105	Native chromatographic sample preparation of serum, plasma and cerebrospinal fluid does not comprise a risk for proteolytic biomarker loss. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 923-924, 102-109.	2.3	3
106	Diffusion tensor imaging patterns differ in bulbar and limb onset amyotrophic lateral sclerosis. Clinical Neurology and Neurosurgery, 2013, 115, 1281-1287.	1.4	32
107	Overexpression of human mutated G93A SOD1 changes dynamics of the ER mitochondria calcium cycle specifically in mouse embryonic motor neurons. Experimental Neurology, 2013, 247, 91-100.	4.1	38
108	MRI in amyotrophic lateral sclerosis: more than a promise. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 710-710.	1.9	0

#	Article	IF	Citations
109	The involvement of the cerebellum in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2013, 14, 507-515.	1.7	75
110	Amyotrophic Lateral Sclerosis: New Insights into Underlying Molecular Mechanisms and Opportunities for Therapeutic Intervention. Antioxidants and Redox Signaling, 2012, 17, 1277-1330.	5.4	58
111	Longitudinal diffusion tensor imaging in amyotrophic lateral sclerosis. BMC Neuroscience, 2012, 13, 141.	1.9	86
112	Specially designed palate prosthesis reconstitutes speech in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 560-561.	2.1	3
113	Endoplasmic reticulum stress and the ER mitochondria calcium cycle in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2012, 13, 166-177.	2.1	67
114	A Randomized, Double Blind, Placebo-Controlled Trial of Pioglitazone in Combination with Riluzole in Amyotrophic Lateral Sclerosis. PLoS ONE, 2012, 7, e37885.	2.5	125
115	The unfolded protein response in models of human mutant G93A amyotrophic lateral sclerosis. European Journal of Neuroscience, 2012, 35, 652-660.	2.6	41
116	Lateral frontal cortex volume reduction in Tourette syndrome revealed by VBM. BMC Neuroscience, 2012, 13, 17.	1.9	37
117	Towards a neuroimaging biomarker for amyotrophic lateral sclerosis. Lancet Neurology, The, 2011, 10, 400-403.	10.2	156
118	A comparison of in vitro properties of resting SOD1 transgenic microglia reveals evidence of reduced neuroprotective function. BMC Neuroscience, 2011, 12, 91.	1.9	19
119	Cerebral Glucose Utilisation in Hepatitis C Virus Infection-Associated Encephalopathy. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 2199-2208.	4.3	38
120	Calcium dysregulation in amyotrophic lateral sclerosis. Cell Calcium, 2010, 47, 165-174.	2.4	259
121	EFNS guidelines on the use of neuroimaging in the management of motor neuron diseases. European Journal of Neurology, 2010, 17, 526.	3.3	75
122	Prefrontal and anterior cingulate cortex abnormalities in Tourette Syndrome: evidence from voxel-based morphometry and magnetization transfer imaging. BMC Neuroscience, 2009, 10, 47.	1.9	134
123	Whole brain-based computerized neuroimaging in ALS and other motor neuron disorders. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 238-248.	2.1	25
124	Role of mitochondria in kainate-induced fast Ca2+ transients in cultured spinal motor neurons. Cell Calcium, 2007, 42, 59-69.	2.4	53
125	Temporospatial coupling of networked synaptic activation of AMPA-type glutamate receptor channels and calcium transients in cultured motoneurons. Neuroscience, 2006, 142, 1019-1029.	2.3	30
126	Dopaminergic properties and function after grafting of attached neural precursor cultures. Neurobiology of Disease, 2006, 21, 587-606.	4.4	40

#	Article	IF	Citations
127	Widespread sensorimotor and frontal cortical atrophy in Amyotrophic Lateral Sclerosis. BMC Neurology, 2006, 6, 17.	1.8	141
128	Rat embryonic motoneurons in long-term co-culture with Schwann cellsâ€"a system to investigate motoneuron diseases on a cellular level in vitro. Journal of Neuroscience Methods, 2005, 142, 275-284.	2.5	57
129	The cellular mRNA expression of GABA and glutamate receptors in spinal motor neurons of SOD1 mice. Journal of the Neurological Sciences, 2005, 238, 25-30.	0.6	21
130	Amyotrophic Lateral Sclerosis: New Developments in Diagnostic Markers. Neurodegenerative Diseases, 2005, 2, 177-184.	1.4	28
131	Ligand-gated channels in early mesencephalic neuronal precursors: immunocytochemical and electrophysiological analysis. European Journal of Neuroscience, 2004, 19, 2371-2376.	2.6	10
132	Kinetic analysis of recombinant mammalian ?1 and ?1? glycine receptor channels. European Biophysics Journal, 2003, 32, 529-536.	2.2	30
133	Kinetic properties of human AMPA-type glutamate receptors expressed in HEK293 cells. European Journal of Neuroscience, 2003, 17, 1173-1178.	2.6	62
134	Prevention of Oxaliplatin-Induced Peripheral Sensory Neuropathy by Carbamazepine in Patients with Advanced Colorectal Cancer. Clinical Colorectal Cancer, 2002, 2, 54-58.	2.3	70
135	Sodium channel function and the excitability of human cutaneous afferents during ischaemia. Journal of Physiology, 2002, 538, 435-446.	2.9	19
136	Ischaemic changes in refractoriness of human cutaneous afferents under thresholdâ€clamp conditions. Journal of Physiology, 2000, 523, 807-815.	2.9	15
137	The chemotherapeutic oxaliplatin alters voltage-gated Na+ channel kinetics on rat sensory neurons. European Journal of Pharmacology, 2000, 406, 25-32.	3.5	248
138	Prevention of peripheral sensory neuropathy (PSN) by carbamazepine in patients with advanced colorectal cancers (ACRC) treated with oxaliplatin. A pilot study. Gastroenterology, 2000, 118, A522.	1.3	1
139	Reproducibility of indices of axonal excitability in human subjects. Clinical Neurophysiology, 2000, 111, 23-28.	1.5	12
140	Changes in excitability indices of cutaneous afferents produced by ischaemia in human subjects. Journal of Physiology, 1999, 518, 301-314.	2.9	29
141	Strengthâ€"duration properties and their voltage dependence at different sites along the median nerve. Clinical Neurophysiology, 1999, 110, 1618-1624.	1.5	28
142	Function of the Hyperpolarization-Activated Inward Rectification in Nonmyelinated Peripheral Rat and Human Axons. Journal of Neurophysiology, 1997, 77, 421-426.	1.8	72
143	Capsaicin blocks tetrodotoxin-resistant sodium potentials and calcium potentials in unmyelinated C fibres of biopsied human sural nerve in vitro. Neuroscience Letters, 1996, 208, 49-52.	2.1	43
144	Immunohistochemical and electrophysiological evidence for Ï‰-conotoxin-sensitive calcium channels in unmyelinated C-fibres of biopsied human sural nerve. Brain Research, 1996, 723, 29-36.	2.2	4

#	Article	IF	Citations
145	Calcium potentials and tetrodotoxin-resistant sodium potentials in unmyelinated C fibres of biopsied human sural nerve. Neuroscience, 1995, 69, 955-965.	2.3	116